Karyopharm Therapeutics Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.8798 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 19.96M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Details
| Name | Karyopharm Therapeutics Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 228 |
| Founded | 2008 |
| Ipo Date | 2013-11-06 |
| Ceo | Richard Paulson |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US48576U2050 |
| Cusip | 48576U205 |
| Cik | 0001503802 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Richard A. Paulson M.B.A. | President, Chief Executive Officer and Director |
| Stuart Poulton | Executive Vice President and Chief Development Officer |
| Dr. Reshma Rangwala M.D., Ph.D. | Executive Vice President, Chief Medical Officer and Head of Research |
| Dr. Sharon Shacham M.B.A., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Lori A. Macomber CPA | EVice President, Chief Financial Officer and Treasurer |
| Kristin Abate | Vice President, Chief Accounting Officer and Assistant Treasurer |
| Brendan Twohig Strong | Senior Vice President of Investor Relations |
| Michael J. Mano J.D. | Executive Vice President, Chief Legal Officer and Secretary |
| James Accumanno J.D. | Chief Compliance Officer |
| Lisa DiPaolo | Executive Vice President and Chief Human Resource Officer |
Contact
| Address | 85 Wells Avenue, 2nd Floor, Suite 210, Newton, Massachusetts 02459-3298, United States |
| Phone | 617 658 0600 |
| Website | https://www.karyopharm.com |